Chembio Diagnostics, Inc.
CEMI · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $48 | $37 | $30 | $34 |
| % Growth | 30.9% | 21.3% | -11.6% | – |
| Cost of Goods Sold | $39 | $34 | $24 | $22 |
| Gross Profit | $10 | $2 | $7 | $12 |
| % Margin | 20.2% | 6.6% | 21.6% | 35% |
| R&D Expenses | $7 | $12 | $10 | $9 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $24 | $25 | $21 | $16 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | -$11 | -$2 | $0 |
| Operating Expenses | $30 | $26 | $29 | $25 |
| Operating Income | -$20 | -$24 | -$22 | -$13 |
| % Margin | -42.2% | -65% | -72.1% | -36.6% |
| Other Income/Exp. Net | $0 | -$10 | -$3 | -$1 |
| Pre-Tax Income | -$23 | -$34 | -$26 | -$14 |
| Tax Expense | $0 | -$0 | -$0 | -$1 |
| Net Income | -$23 | -$34 | -$26 | -$14 |
| % Margin | -48.2% | -91.8% | -83.8% | -39.7% |
| EPS | -0.96 | -1.4 | -1.34 | -0.81 |
| % Growth | 31.4% | -4.5% | -65.4% | – |
| EPS Diluted | -0.96 | -1.4 | -1.34 | -0.81 |
| Weighted Avg Shares Out | 24 | 24 | 19 | 17 |
| Weighted Avg Shares Out Dil | 24 | 24 | 19 | 17 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $3 | $3 | $847 |
| Depreciation & Amortization | $6 | $3 | $3 | $1 |
| EBITDA | -$15 | -$21 | -$19 | -$861 |
| % Margin | -30.2% | -57.1% | -63.2% | -2,498.3% |